Business, energy, technology, markets and global industry news from Business News Today

CAPLYTA

PharmaDeviceNews CAPLYTA
Representative image of a clinical consultation on long-term schizophrenia care, as Johnson & Johnson’s CAPLYTA FDA label update sharpens focus on relapse prevention, treatment stability, and durability in neuropsychiatric therapy.
Pharma & Biotech

Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability

Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.

Read More
Representative image of pharmaceutical tablets and clinical tools, reflecting ongoing advancements in adjunctive therapies like CAPLYTA (lumateperone) for major depressive disorder.
Pharma & Biotech

Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope

Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double

Read More